Form 4: Kiniksa Pharmaceuticals CEO Sanj K Patel Reports Share Transactions
SEC Form 4 Filing
Sanj K Patel, Chairman and CEO of Kiniksa Pharmaceuticals International, plc, reports the vesting and disposal of restricted share units and related tax withholding.
Summary
- On April 7, 2025, Sanj K Patel, Chairman and CEO of Kiniksa Pharmaceuticals International, plc, executed transactions involving Class A Ordinary Shares.
- Patel vested 9,992 Restricted Share Units (RSUs), each representing a contingent right to receive one Class A Ordinary Share.
- Following the vesting, Patel disposed of 4,832 shares to cover tax obligations at a price of $20.28 per share.
- After these transactions, Patel directly owns 96,674 Class A Ordinary Shares and indirectly owns 109,795 shares through The Marina 2016 Irrevocable Trust.
- Patel also directly owns 9,991 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing insider transactions, which is neutral in sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives regarding their holdings of company stock.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies, ensuring transparency of insider transactions.
- The vesting schedule of the RSUs (25% annually over four years) is a common vesting structure in the industry.
- Disposal of shares to cover tax obligations upon vesting of RSUs is a typical occurrence for executives receiving equity compensation.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they reflect routine executive compensation and tax obligations.
- The filing provides transparency to stakeholders regarding executive stock ownership.
Key Dates
| Date | Description |
|---|---|
| June 23, 2016 | Date of The Marina 2016 Irrevocable Trust |
| April 7, 2022 | Grant date of the Restricted Share Units (RSUs) that vest over a four-year period. |
| April 7, 2025 | Date of the reported transactions: vesting of RSUs and disposal of shares for tax obligations. |
| April 9, 2025 | Date of signature on the Form 4 filing. |
Keywords
Kiniksa Pharmaceuticals, Sanj K Patel, Form 4, Share Transactions, Restricted Share Units, Class A Ordinary Shares, Beneficial Ownership, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.